Ramtin Agah
Known title: Chief Medical OfficerCIK: 0001862617
Ramtin Agah's purchase track record
How the stock did after each of Ramtin Agah's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
8
of 8 since June 7, 2022
Stock higher 6 months later
63%
3 months: 63%
Median 6-month return
+2.5%
3 months: +14.6%
Beat the S&P 500
38%
median -4.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/21/2026 | RNXT | $10K | -5.0% | -13.2% | +9.1% |
| 12/30/2025 | RNXT | $9K | +15.4% | +12.0% | +8.8% |
| 12/16/2025 | RNXT | $10K | +14.6% | +4.4% | +10.5% |
| 12/5/2025 | RNXT | $10K | -16.1% | -7.3% | +7.5% |
| 11/21/2025 | RNXT | $18K | +14.7% | +10.8% | +13.2% |
| 6/5/2025 | RNXT | $29K | -15.0% | -32.1% | +15.4% |
| 4/8/2025 | RNXT | $76K | +62.5% | +52.5% | +34.8% |
| 6/7/2022 | RNXT | $10K | +18.5% | +0.7% | -5.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RNXT | ▲ Buy | Open Market | 10,000 | $10K | 1/21/2026 | View on chart |
| RNXT | ▲ Buy | Open Market | 9,795 | $8K | 12/31/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 205 | $169 | 12/30/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 12,000 | $10K | 12/16/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 10,000 | $10K | 12/5/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 12,000 | $10K | 11/24/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 10,000 | $8K | 11/21/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 21,000 | $29K | 6/5/2025 | View on chart |
| RNXT | ▼ Sell | Gift | 400,000 | $0 | 4/22/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 15,000 | $14K | 4/15/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 20,000 | $16K | 4/11/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 30,000 | $24K | 4/9/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 26,000 | $22K | 4/8/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 40,983 | — | 1/26/2024 | View on chart |
| RNXT | ▲ Buy | Open Market | 5,182 | $10K | 6/7/2022 | View on chart |
| RNXT | ▼ Sell | Gift | 975,000 | $0 | 3/16/2022 | View on chart |
| RNXT | ▼ Sell | Gift | 975,000 | $0 | 3/16/2022 | View on chart |
| RNXT | ▼ Sell | Other | 1,295 | — | 8/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
RenovoRx publishes peer-reviewed case series in oncology journal
RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.
RenovoRx publishes peer-reviewed case series in oncology journal. RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.